Tian Zhang

No bio available.

Financial relationships

  • Attribution: 
    Self
    Type of financial relationship: 
    Grant Or Contract
    Ineligible company: 
    Acerta, Novartis, Merrimack, Abbvie/StemCentrx, Merck, Regeron, Mirati Therapeutics, Janssen, AstraZeneca, Pfizer, OmniSeq, Personal Genome Diagnostics, Astellas
    Topic: 
    PI (research funding)
    Date added: 
    03/22/2022
  • Attribution: 
    Self
    Type of financial relationship: 
    Professional Services
    Ineligible company: 
    Pfizer, MJH Associates, Vaniam, Aptitude Health, PeerView, Clinical Care Options
    Topic: 
    Consultant
    Date added: 
    03/22/2022
  • Attribution: 
    Self
    Type of financial relationship: 
    Professional Services
    Ineligible company: 
    Merck, Exelixis, Sanofi-Aventis, Janssen, AstraZeneca, Pfizer, Amgen, BMS, Pharmacyclics, SeaGen, Calithera, Dendreon, QED Therapeutics, Eisai, Aveo Pharmaceuticals, Bayer, Eli Lilly
    Topic: 
    Advisory Board
    Date added: 
    03/22/2022
Return to 109 DIVISION OF HEM/ONC: ONCOLOGY BOARD REVIEW CONFERENCE " Bladder Cancer 2 + Fellow Cases " (041422)